Physician profile
Sharon E Ross
NPI 1518966639
$2,174.20
in general payments reported to CMS, 2019-2025
23 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $65.02 · 2021: $143 · 2022: $416 · 2023: $285 · 2024: $430 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.98 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.36 | 2019-2025 | Orilissa, Lo Loestrin Fe, Oriahnn |
| Exact Sciences Corporation | $231.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $205.27 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $150.15 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $145.76 | 2019-2022 | |
| Axonics, INC. | $141.23 | 2022 | |
| Millicent US INC | $140.91 | 2019-2025 | Femring, Intrarosa |
| Duchesnay USA Incorporated | $111.90 | 2019 | |
| Aspira Women'S Health INC | $99.81 | 2019-2023 | Ova1 |
| Therapeuticsmd, INC. | $96.91 | 2019-2022 | |
| Coopersurgical, INC. | $90.30 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Biogen, INC. | $56.16 | 2024 | Zurzuvae |
| Mayne Pharma Commercial LLC | $47.90 | 2023-2024 | |
| Vertical Pharmaceuticals, LLC | $44.76 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.67 | 2019-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $27.94 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $27.49 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.00 | 2019 | |
| Evofem Biosciences, INC. | $20.23 | 2025 | Solosec, Phexx, Phexxi |
| Kowa Pharmaceuticals America, INC. | $19.47 | 2023 | Seglentis |
| Organon LLC | $15.20 | 2022 | |
| Agile Therapeutics, INC. | $14.93 | 2021 | |
| Scynexis, INC. | $14.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.